Internal Medicine, Cardiovascular Disease · Sacramento, CA
NPI
1285671222
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
500 University Ave.
Sacramento, CA, 95825
Phone (916) 830-2000
Medicare paid, 2024
$277K
4,186 services
Medicare patients, 2024
1,085
Average age 75
Drug cost, 2024
$1.9M
8,616 prescriptions
Company payments, 2024
$219
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel D Vanhamersveld was code 93000 (electrocardiogram), 1,345 times for 940 patients. In total Daniel D Vanhamersveld billed 4,186 services in 32 codes, and Medicare paid $277K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-11-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93000 Electrocardiogram | Office | 1,345 | 940 | $10.89 | $15K |
| 99214 Office E&M - Established | Office | 1,279 | 849 | $96.13 | $123K |
| 99213 Office E&M - Established | Office | 591 | 368 | $75.98 | $45K |
| 93306 Echocardiography (TTE/TEE) | Office | 380 | 362 | $162.01 | $62K |
| 93793 Care Management/Coordination | Office | 280 | 16 | $9.44 | $2,642 |
| 99204 Office E&M - New | Office | 115 | 115 | $116.21 | $13K |
| 71271 CT/CTA - Chest | Office | 24 | 24 | $109.39 | $2,625 |
| 75571 CT/CTA - Chest | Office | 21 | 21 | $73.62 | $1,546 |
| 93325 Echocardiography (TTE/TEE) | Office | 18 | 18 | $22.50 | $405 |
| 93351 Echocardiography (TTE/TEE) | Office | 18 | 18 | $191.20 | $3,442 |
| 93320 Echocardiography (TTE/TEE) | Office | 17 | 17 | $47.72 | $811 |
| 93244 Electrocardiogram | Office | 15 | 15 | $20.13 | $302 |
| 93242 Electrocardiogram | Office | 15 | 15 | $11.57 | $174 |
| 71250 CT/CTA - Chest | Office | 12 | 12 | $73.85 | $886 |
By year: 2022 $316K for 5,046 services; 2023 $302K for 4,659 services; 2024 $277K for 4,186 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel D Vanhamersveld prescribed most often to Medicare patients was Olmesartan Medoxomil, with 862 prescriptions and refills. In total Daniel D Vanhamersveld wrote 8,616 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Olmesartan Medoxomil Generic | 862 | 2,269 | 293 | $17K |
| Rosuvastatin Calcium Generic | 817 | 2,053 | 250 | $19K |
| Losartan Potassium Generic | 567 | 1,551 | 187 | $5,485 |
| Furosemide Generic | 487 | 1,118 | 170 | $2,204 |
| Entresto Sacubitril/Valsartan | 360 | 800 | 87 | $508K |
| Xarelto Rivaroxaban | 360 | 862 | 103 | $475K |
| Carvedilol Generic | 355 | 864 | 107 | $2,608 |
| Eliquis Apixaban | 345 | 790 | 103 | $452K |
| Amlodipine Besylate Generic | 338 | 831 | 94 | $1,866 |
| Metoprolol Succinate Generic | 305 | 776 | 92 | $4,150 |
| Nebivolol Hcl Generic | 244 | 618 | 81 | $15K |
| Spironolactone Generic | 234 | 590 | 72 | $1,811 |
| Telmisartan Generic | 199 | 531 | 61 | $7,760 |
| Indapamide Generic | 187 | 487 | 62 | $2,199 |
| Valsartan Generic | 181 | 506 | 58 | $5,904 |
Brand drugs: 1,572 claims; generic drugs: 7,015 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Daniel D Vanhamersveld $219 ($219 in general payments such as food, travel and fees) from 8 companies. The largest payer was Novartis Pharmaceuticals Corporation with $55.09.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 3 | $55.09 |
| Kiniksa Pharmaceuticals International, plc KNSA | 1 | $38.62 |
| Pfizer Inc. PFE | 2 | $33.21 |
| Merck Sharp & Dohme LLC MRK | 1 | $26.49 |
| Heartflow, Inc. HTFL | 1 | $18.34 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $17.97 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $14.64 |
| Amgen Inc. AMGN | 1 | $14.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.